Non-small Cell Lung Cancer Treatment Market Growing Trade Among Emerging Economies Opening New Opportunities | Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd

Rising product launches of biosimilars of Bevacizumab is expected to boost the global non-small cell cancer market growth over the forecast period. For instance, in July 2019, Amgen and Allergan plc collaborated and launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in combination with chemotherapy for Non-small cell lung cancer. Furthermore, in 2018, F. Hoffmann-La Roche AG launched atezolizumab under the brand name Tecentriq for the treatment of Non-small cell lung cancer (NSCLC) in India. Moreover, in 2019 Sandoz, a subsidiary of Novartis AG, launched generic oncology medicine, gefitinib, indicated for adult patients with metastatic non-small cell lung cancer.

Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/241

Key companies are involved in research and development activities, in order to innovate novel products and gain a competitive edge in the market. For instance, in March 2019, Eli Lily and Company announced the positive result for its Phase 3 RELAY study of CYRAMZA (ramucirumab), meeting primary endpoint of progression-free survival (PFS) and exhibited impressive improvement in patients that lived without their cancer spreading or growing after treatment. CYRAMZA is indicated for the treatment of Non-small cell lung cancer.

Key Takeaways

• The global non-small cell lung cancer market is expected to expand, registering a CAGR of 9.3% over the forecast period (2019-2027). This is owing to rising product launches for non-small cell lung cancer treatment.

• On the basis of type, adenocarcinoma segment is expected to account for the largest share in the market by 2027, owing to rising cases of adenocarcinoma. According to the American Cancer Society (ACS) data of October 2019, lung adenocarcinoma accounts for 40% of all lung cancers cases, globally. It is more prone in women. Furthermore, according to the same source, younger population (aged 20-46), who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers, globally.

• Key companies involved in the global non-small cell lung cancer market are Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/241

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Non-small Cell Lung Cancer Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Non-small Cell Lung Cancer Treatment Industry Impact

Chapter 2 Global Non-small Cell Lung Cancer Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Non-small Cell Lung Cancer Treatment (Volume and Value) by Type
2.3 Global Non-small Cell Lung Cancer Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Non-small Cell Lung Cancer Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 6 East Asia Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 7 Europe Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 8 South Asia Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 9 Southeast Asia Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 10 Middle East Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 11 Africa Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 12 Oceania Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 13 South America Non-small Cell Lung Cancer Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Non-small Cell Lung Cancer Treatment Business
Chapter 15 Global Non-small Cell Lung Cancer Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology